Fangzhou Dou
Qingdao, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The dual role of TRPA1 in dextran sulfate sodium (DSS)-induced murine colitis: Suppression alleviates acute inflammation but exacerbates subacute disease.
Journal: Bioscience trends
Published: January 25, 2026
Trpa1 knockout favors colon tumorigenesis in dextran sulfate sodium (DSS)-induced colitis mice.
Journal: Drug discoveries & therapeutics
Published: June 22, 2025
Fitusiran: The first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels.
Journal: Drug discoveries & therapeutics
Published: April 13, 2025
Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs).
Journal: Intractable & rare diseases research
Published: February 19, 2025
Tailored to fit: China optimizes policies and regulations regarding drug registration and review to promote innovation in traditional Chinese medicine.
Journal: Drug discoveries & therapeutics
Published: July 21, 2024
Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
Journal: Drug discoveries & therapeutics
Published: January 14, 2024
Involvement of adaptive immune responses in a model of subacute colitis induced with dextran sulfate sodium in C57BL/6 mice.
Journal: Drug discoveries & therapeutics
Published: July 12, 2023
Is targeting angiotensin-converting enzyme 2 (ACE2) a prophylactic strategy against COVID-19?
Journal: Bioscience trends
Published: December 25, 2022
Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Journal: Drug discoveries & therapeutics
Published: October 30, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026